Plain-English translation of NCT04240054 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a four-drug combination called VICD—which includes , , , and —as a starting treatment for newly diagnosed multiple myeloma (a blood cancer) in patients whose kidneys have been affected by the disease. Researchers want to see if adding to the three other drugs helps more patients achieve a very good response before they undergo a stem cell transplant. The study includes a small safety group first, followed by a larger group of patients.
Multiple myeloma can damage the kidneys, and patients with kidney problems have fewer treatment options and worse outcomes. This medication combination may work better than existing treatments even for patients with kidney damage, potentially improving their chances of remission before transplant.
You likely qualify if…
You likely don't qualify if…
If you join, you would receive four medications given on a repeating schedule over several weeks: as an injection, as an IV infusion, as an IV infusion, and as a tablet or IV dose. After completing this treatment phase, you would proceed to your planned stem cell transplant. You would have regular blood tests and clinic visits to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States